key: cord-0686665-tf6tqkjw
authors: Arshadi, Maniya; Fardsanei, Fatemeh; Deihim, Behnaz; Farshadzadeh, Zahra; Nikkhahi, Farhad; Khalili, Farima; Sotgiu, Giovanni; Shahidi Bonjar, Amir Hashem; Centis, Rosella; Migliori, Giovanni Battista; Nasiri, Mohammad Javad; Mirsaeidi, Mehdi
title: Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Detection: A Systematic Review With Meta-analysis
date: 2022-04-07
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2022.870738
sha: aff552e07a2a183bb3e4f16bb6fbe3d74d505310
doc_id: 686665
cord_uid: tf6tqkjw

INTRODUCTION: Reverse transcription-polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 is time-consuming and sometimes not feasible in developing nations. Rapid antigen test (RAT) could decrease the load of diagnosis. However, the efficacy of RAT is yet to be investigated comprehensively. Thus, the current systematic review and meta-analysis were conducted to evaluate the diagnostic accuracy of RAT against RT-PCR methods as the reference standard. METHODS: We searched the MEDLINE/Pubmed and Embase databases for the relevant records. The QUADAS-2 tool was used to assess the quality of the studies. Diagnostic accuracy measures [i.e., sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratios (PLR), negative likelihood ratios (NLR), and the area under the curve (AUC)] were pooled with a random-effects model. All statistical analyses were performed with Meta-DiSc (Version 1.4, Cochrane Colloquium, Barcelona, Spain). RESULTS: After reviewing retrieved records, we identified 60 studies that met the inclusion criteria. The pooled sensitivity and specificity of the rapid antigen tests against the reference test (the real-time PCR) were 69% (95% CI: 68–70) and 99% (95% CI: 99–99). The PLR, NLR, DOR and the AUC estimates were found to be 72 (95% CI: 44–119), 0.30 (95% CI: 0.26–0.36), 316 (95% CI: 167–590) and 97%, respectively. CONCLUSION: The present study indicated that using RAT kits is primarily recommended for the early detection of patients suspected of having COVID-19, particularly in countries with limited resources and laboratory equipment. However, the negative RAT samples may need to be confirmed using molecular tests, mainly when the symptoms of COVID-19 are present.

COVID-19 epidemic is caused by SARS-CoV-2 and began in December 2019 in Wuhan, Hubei, China. The virus, which has infected more than 260 million people and killed more than 4.5 million as of December 10, 2021, can cause various conditions, from asymptomatic to lightningfast respiratory failure (1, 2) . Given the rapid community and congregate setting transmission and high pathogenicity, reliable and early identification of SARS-CoV-2 are critical (3) . Currently, COVID-19 diagnostic techniques are classified into two categories: (1) methods that evaluate clinical samples directly for virus particles, antigens, or nucleic acids; and (2) serological assays for anti-SARS-CoV-2 antibodies (4). For COVID-19 diagnosis, the reverse transcriptase-polymerase chain reaction (RT-PCR) is the gold standard for sputum, nasopharyngeal swabs, bronchoalveolar lavage fluid, and nasal and nasal oral fluids (5) . However, its widespread use is limited by the necessity for expensive laboratory equipment and welltrained laboratory personnel (6) . Furthermore, these tests are frequently challenged for being too sensitive since they do not distinguish between live infections and non-viable viral remaining genetic pieces. On the other hand, these diagnostic tests can tell if a disease is present in a person but not define its contagiousness (7) . Recent studies have shown rapid antigen test (RAT) to be a more practical, less costly, and faster technique, especially in the early days following symptoms, although less sensitive (8) . Antigen diagnostic assays identify proteins from a live virus in 15-30 min, such as the spike protein, nucleocapsid protein, or both (9) . It is cost-effective, easy to use outside of laboratory facilities, requires no experienced workers, and may be used on a wide range of patients. Many of these tests do not need the use of analyzers or readers, making them less costly and more portable (10) . Another benefit of employing an antigen test is that it may discover vast numbers of asymptomatic carriers who often migrate from one location to another. This test may also be used as a preliminary screening test before RT-PCR (11) . However, despite their excellent specificity, the sensitivity of RAT kits is not as great as other molecular assays (12) . Thus, the efficacy of RAT is yet to be investigated comprehensively. Therefore, the current systematic review and meta-analysis were conducted to evaluate the diagnostic accuracy of RAT against RT-PCR methods as the reference standard.

This study was conducted and reported according to the PRISMA guidelines (13) . 

The MEDLINE/PubMed and Embase were searched for relevant studies published up to March 8 2022. The combination of the following keywords was used: (Sensitivity and Specificity) OR (predictive value) OR (accuracy) AND (COVID-19) OR (SARS-CoV-2). We used a combination of free text and MeSH terms to identify the relevant studies. Studies were included if they used commercial RAT as their index test and RT-PCR as their reference test to detect SARS-CoV-2 and provide sufficient data to compute sensitivity and specificity. Only English studies were included. Duplicate publications, protocols, reviews, conference abstracts, and in-house tests were excluded.

Two reviewers (MA and AFS) designed a data extraction form. These reviewers extracted data from all eligible studies, and consensus resolved differences. The following items were extracted from each article: the name of the first author, year of publication, study location, RT-PCR test, number of confirmed SARS-CoV-2 positive cases, cycle threshold (Ct) value, presence of symptoms, specimen types, and type of antigen tests.

The methodological quality of the studies was assessed using the QUADAS-2 checklist (14) . The following items are evaluated in this checklist: Patient selection: describes methods of patient selection; index text: describes the index test and how it was conducted and interpreted; reference standard: describes the reference standard (standard gold test) and how it was conducted and interpreted; flow and timing: describes any patients who did not receive the index tests or reference standard and defines the interval and any interventions between index tests and the reference standard.

Statistical analyses were performed with Meta-DiSc (version 1.4, Cochrane Colloquium, Barcelona, Spain) software. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals between antigen rapid diagnostic tests and the reference standard were assessed. A random-effects model was used to pool the estimated effects. The random-effects model was used because of the estimated heterogeneity of the true effect sizes. Diagnostic accuracy measures [(i.e., the summary receiver operating characteristic (SROC) curve and the summary positive likelihood ratios (PLR), negative likelihood ratios (NLR), and DOR] were calculated. Sensitivity is the proportion of positive test results among those with the target infection. Specificity is the proportion of negative test results among those without the disease. The PLR measures how frequently a positive test is found in infected vs. non-infected individuals. On the other hand, the NLR measures how likely a negative result is in infected vs. non-infected individuals. Tests with pooled PLR values >10 and a pooled NLR value of <0.1 have the greater discriminating ability (15, 16) .

The DOR or the odds of a positive result in infected individuals compared to the odds of a positive result in noninfected individuals. It is calculated according to the formula: DOR = (TP/FN)/(FP/TN). DOR depends significantly on the sensitivity and specificity of a test. A high specificity and sensitivity test with a low rate of false positives and false negatives have high DOR (16) .

The area under the curve (AUC) serves as a global measure of test performance; a value of 1 indicates perfect accuracy (16, 17) .

Deek's test was used to identify the risk of publication bias based on parametric linear regression methods (18) . Subgroup analysis was conducted using several study characteristics separately.

Studies included and excluded through the review process are summarized in Figure 1 . A total of 21,627 records were found in the initial search; after removing duplicate articles, titles and abstracts of 14,973 references were screened. One hundred ninety-seven articles were selected for a full-text review. Of these, 137 were excluded because they did not present primary data. Finally, 60 were chosen ( Table 1 ) . Of these, 148 were excluded because they did not present primary data (13, ; or the Ag-RDT was not commercially available (16) , 132-164, leaving 133 studies to be included in the systematic review.

A total of 43,034 samples (8,360 with and 34,674 without COVID-19) were investigated. The included studies came from different countries, with the majority from Germany (n = 9), followed by Spain and Italy (n = 8). Participants in the included studies varied from being either symptomatic only (n = 13), asymptomatic only (n = 9), or a mix of both (n = 24). The included studies had either adults only or participants of all ages. Three studies evaluated the diagnostic performance of antigen tests with nasal/oral swab specimens, and 52 the accuracy of antigen tests with nasopharyngeal swab specimens. Twentyseven studies provided Ct values of positive RT-PCRs. The investigated commercial RAT was Panbio, SD Biosensor, Roche, COVID-19 Ag Respi-Strip, LUMIPULSE, and BinaxNOW. All RAT detected nucleocapsid or spike proteins.

Forty-five studies were judged to have a high risk of bias in the patient selection domain. Based on the QUADAS 2 tool, in these studies, patient selection methods were not fully described. Furthermore, a high risk of bias was found in the domain of the index tests in 27 studies. In thesis studies, it was not clear whether the index test results were interpreted without knowledge of the results of the reference standard. All studies underwent a reference standard and were judged to have a low risk of bias in the flow and timing domains ( Table 2) .

The pooled sensitivity and specificity of the RAT were 69% (95% CI: 68-70) and 99% (95% CI: 99-99) (Figures 2, 3) . The PLR, NLR, DOR, and the AUC estimates were found to be 72 (95% CI: 44-119), 0.30 (95% CI: 0.26-0.36), 316 (95% CI: 167-590), and 97%, respectively. The AUC estimates in this report also represented a high level of test accuracy (Figure 4) . Deek's test result indicated no likelihood for publication bias (P > 0.05).

The sensitivity for each subgroup was lower than the specificity ( Table 3 ). The sensitivity of RAT was slightly higher in symptomatic (65%) than asymptomatic patients (64%). Kits from different manufacturers exhibited various sensitivity. Lumipulse showed the highest sensitivity (87%) followed by SD Biosensor (76%), Panbio (75%), Roche (60%), BinaxNOW (57%) and Respi-Strip (39%). The sensitivity of the nasopharyngeal swab was higher (70%) than that where throat or saliva swabs were used (52%). The sensitivity of RAT kits ranged from 65 to 71% when Ct values were 20-31. The RAT kits had a similar sensitivity based on the antigen detection technology (i.e., immunochromatography and chemiluminescent immunoassay). The pooled sensitivity for Ct value ≤25 was markedly better, at 71.0%, compared to the group with Ct value >26, at 67.0%.

Diagnostic testing for SARS-CoV-2 is essential for the overall COVID-19 preventive and control plan. With the number of COVID-19 cases and mortalities increasing worldwide, it is more important than ever to look into the usefulness of existing diagnostic tests and the optimal settings to achieve the most accuracy and consistency (4).

RT-PCR has been accepted as the gold standard for SARS-CoV-2 infection diagnosis. Despite its high sensitivity and specificity, this method is expensive and needs well-equipped facilities (79) . Moreover, the reporting of RT-PCR data may take longer than expected in many cases owing to large sample numbers and a lack of technical assistance, resulting in delayed patient care and outbreak control (80) . Consequently, a focus on using RAT kits was required to bridge diagnostic gaps. RAT available on the market is steadily rising (81) . RATs are straightforward to conduct and interpret at the point of care by minimally educated health professionals (82, 83) .

We summarized the data from 60 studies evaluating the accuracy of RAT. The sensitivity and specificity were assessed using a reliable reference standard test. The pooled estimates of sensitivity and specificity of the RAT against RT-PCR were 69 and 99%, respectively.

Similarly, Lee et al. (84) computed a sensitivity of 68% and a specificity of 99% for 24 studies focused on RAT (84) . The metaanalysis of Wang et al. (85) showed a sensitivity of 79% and a specificity of 100%, pooling 14 studies (85) . Likewise, according to the meta-analysis performed by Brummer et al., the sensitivity and specificity of RAT were 71.2 and 98.9%, respectively (81) . In a study by Chen et al., the diagnostic accuracy of RAT for SARS-CoV-2 in community participants was assessed. The overall sensitivity and specificity were 82 and 100%, respectively (86) .

The World Health Organization (WHO) recommends that a RAT kit reach a minimum performance criterion of at least 80% sensitivity and 97% specificity (87) . Furthermore, RAT findings will be most acceptable in places where community transmission is continuous (5% test positive rate), according to WHO standards (87) . RAT positive predictive value is poor when there is no or low transmission (many false positives). RT-PCR is better as a first-line diagnostic tool than confirming positive RAT (88) .

In our meta-analysis, sensitivity below 80% and high specificity were found. Sensitivity differences of the mentioned meta-analyses may be related to the characteristics of study participants, including whether patients are symptomatic or asymptomatic and the time of sampling after the onset of symptoms. The results of the current meta-analysis support the statement of the Infectious Diseases Society of America (IDSA) guidelines on the correlation between RAT sensitivity and viral load, symptoms, and the timing of the test (89) .

Similar to a previous study, low Ct values, the RT-PCR correlate for high virus concentration, resulted in significantly higher RAT sensitivity (90, 91) .

RAT also showed higher sensitivity in symptomatic patients than asymptomatic patients (pooled sensitivity 65 vs. 64%), which is to be expected given that samples from patients with symptoms have been shown to contain the highest virus concentrations (90) . similarly, studies that enrolled symptomatic patients showed a lower range of Ct values than studies enrolling asymptomatic patients (90) (91) (92) (93) .

Considering the epidemiological context, clinical history, and available testing funds, clinical decision-making should be used to determine whether negative RAT results necessitate confirmatory testing with RT-PCR or repeat testing with RAT (within 48 h) if RT-PCR assay is not available (94) . Owing to the RAT sensitivity (69%), these tests should be used in the initial screening, contact tracing, and monitoring of the outbreak in different countries (87) .

There are some limitations. First, we could not assess the correlation between sample conditions (such as storage or transportation) and the sensitivity of RAT. Second, the potential influence of different genetic and structural mutations of SARS-CoV-2 could not be evaluated because of the limited available information. Variants of SARS-CoV-2 may be differently detected by RAT. Finally, the sensitivity of RAT may differ depending on the manufacturer and the country where the kits are produced.

In conclusion, the present study showed that RAT is recommended mainly for the early detection of patients with presumed COVID-19, especially in countries with limited resources and laboratory equipment. However, negative RAT samples should be confirmed by molecular tests, mainly in the presence of COVID-19 symptoms.

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

All authors participated in the drafting and revision of the manuscript, as well as in the approval of the final version.

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Molecular diagnostic assays for COVID-19: an overview

Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

Rapid diagnosis of COVID-19 in the first year of the pandemic: a systematic review

Molecular diagnostic technologies for COVID-19: Limitations and challenges

Twenty-five years of quantitative PCR for gene expression analysis

Roadmap to the bioanalytical testing of COVID-19: from sample collection to disease surveillance

Comparison of rapid antigen tests for COVID-19

Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19

COVID-19 testing: one size does not fit all

Diagnosis of COVID-19 in symptomatic patients: an updated review

Scaling up COVID-19 rapid antigen tests: promises and challenges

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Group * Q-QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

Understanding the properties of diagnostic tests-Part 2: likelihood ratios

Measures of diagnostic accuracy: basic definitions

Conducting systematic reviews of diagnostic studies: didactic guidelines

The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed

Field evaluation of a rapid antigen test (Panbio TM COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres

Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting

Performance of a point-of-care test for the rapid detection of SARS-CoV-2 antigen

Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison

Diagnostic accuracy of two commercial SARS

Antigen-detecting rapid tests at the point of care in community-based testing centers

Comparative diagnostic performance of rapid antigen detection tests for COVID-19 in a hospital setting

Comparative analysis of antigen and molecular tests for the detection of Sars-CoV-2 and related variants: a study on 4266 samples

Implementing SARS-CoV-2 Rapid antigen testing in the emergency ward of a swiss university hospital: The INCREASE study

Performance of a rapid antigen test in the diagnosis of SARS-CoV-2 infection

High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection

Field evaluation of COVID-19 antigen tests versus RNA based detection: potential lower sensitivity compensated by immediate results, technical simplicity, low cost

Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection

Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection

Clinical assessment of the Roche SARS-CoV-2 rapid antigen test

Five antigen tests for SARS-CoV-2: virus viability matters

Immunochromatography and chemiluminescent enzyme immunoassay for COVID-19 diagnosis

Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection

Performance of the BinaxNOW coronavirus disease 2019 (COVID-19) Antigen Card test relative to the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) realtime reverse transcriptase polymerase chain reaction (rRT-PCR) assay among symptomatic and asymptomatic healthcare employees

The comparative clinical performance of four SARS-CoV-2 rapid antigen tests and their correlation to infectivity in vitro

Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit

Clinical evaluation of Roche SD Biosensor rapid antigen test for SARS-CoV-2 in municipal health service testing site, the Netherlands

Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care has a High Sensitivity in Symptomatic and Asymptomatic Patients with Higher Risk for Transmission and Older Age

Performance evaluation of a lateral flow assay for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis

Evaluation of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: implications for screening in a school setting

Utility of antigenbased rapid diagnostic test for detection of SARS-CoV-2 virus in routine hospital settings

Analytical performances of the point-of-care SIENNA TM COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: a prospective evaluation during the COVID-19 second wave in France

Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admission

Performance evaluation of serial SARS-CoV-2 rapid antigen testing during a nursing home outbreak

Evaluation of a rapid antigen test (Panbio TM COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients

Evaluation of Lumipulse R G SARS-CoV-2 antigen assay automated test for detecting SARS-CoV-2 nucleocapsid protein (NP) in nasopharyngeal swabs for community and population screening

Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19

Diagnostic accuracy of PanbioTM rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2

Accuracy of a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior nasal swabs

Diagnostic accuracy of the panbio severe acute respiratory syndrome coronavirus 2 antigen rapid test compared with reverse-transcriptase polymerase chain reaction testing of nasopharyngeal samples in the pediatric population

Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B. 1351 variant in the Eastern Cape, South Africa

SARS-CoV2 antigen in whole mouth fluid may be a reliable rapid detection tool

Point of care testing using rapid automated antigen testing for SARS-COV-2 in Care Homes-an exploratory safety, usability and diagnostic agreement evaluation. medRxiv

Performance of SARS-CoV-2 rapid antigen test compared with realtime RT-PCR in asymptomatic individuals

Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study

Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. medRxiv

The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients

Multicenter evaluation of a fully automated highthroughput SARS-CoV-2 antigen immunoassay. medRxiv

Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report

Use of lateral flow devices allows rapid triage of patients with SARS-CoV-2 on admission to hospital

Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test

Antigenbased testing but not real-time polymerase chain reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture

Urgent need of rapid tests for SARS CoV-2 antigen detection: evaluation of the SD-biosensor antigen test for SARS-CoV-2

Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Real-life validation of the Panbio TM COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection

Rapid chromatographic immunoassay-based evaluation of COVID-19: a cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India

Analysis of a persistent viral shedding patient infected with SARS-CoV-2 by RT-qPCR, FilmArray Respiratory Panel v2. 1, antigen detection

Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites-Pima County

Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms

Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context

Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Sensitivity and specificity of lateral flow antigen test kits for covid-19 in asymptomatic population of quarantine centre of province 3

Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium

Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs

Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples

COVID-19 in-vitro diagnostics: state-of-the-art and challenges for rapid, scalable, high-accuracy screening

Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients

The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. medRxiv

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital

Comparing the diagnostic accuracy of rapid antigen detection tests to real time polymerase chain reaction in the diagnosis of SARS-CoV-2 infection: a systematic review and meta-analysis

Evaluation of the diagnostic accuracy of COVID-19 antigen tests: a systematic review and meta-analysis

Diagnostic accuracy of SARS-CoV-2 antigen tests for community transmission screening: a systematic review and meta-analysis

Antigen-Detection in the Diagnosis of SARS-CoV-2 Infection: Interim Guidance. World Health Organization

Diagnostics SARS-CoV-2 Diagnostic Pipeline. Foundation for innovative new diagnostics

The infectious diseases society of America guidelines on the diagnosis of COVID-19: antigen testing

Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and metaanalysis

Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults using an ultrasensitive and quantitative antigen assay

Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea

Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs

To Test, Perchance to Diagnose: Practical Strategies for Severe Acute Respiratory Syndrome Coronavirus 2 Testing, Open Forum Infectious Diseases

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2022 Arshadi, Fardsanei, Deihim, Farshadzadeh, Nikkhahi, Khalili, Sotgiu, Shahidi Bonjar, Centis, Migliori, Nasiri and Mirsaeidi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.